Dynamic Toll-like receptor expression predicts outcome of sclerotherapy for lymphatic malformations with OK-432 in children

Abstract Background Sclerotherapy with OK-432 is recommended as a first-line treatment for lymphatic malformations. However, 40% of patients show poor response, defined by involution to

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of surgical research 2014-03, Vol.187 (1), p.197-201
Hauptverfasser:	Reismann, Marc, PhD, Ghaffarpour, Nader, MD, Luvall, Ethel, MSc, Jirmo, Adan C., PhD, Winqvist, Ola, PhD, Radtke, Josephine, MD, Wester, Tomas, PhD, Claesson, Gösta, PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Child, Preschool Children Drug Monitoring - methods Female Flow Cytometry Humans Infant Ligands Lipopolysaccharides - pharmacology Lymphatic Abnormalities - metabolism Lymphatic Abnormalities - therapy Lymphatic malformation Male Monocytes - drug effects Monocytes - physiology OK-432 Picibanil - therapeutic use Predictive Value of Tests Sclerotherapy Sclerotherapy - methods Surgery Toll-like receptor Toll-Like Receptor 4 - metabolism Toll-Like Receptor 7 - metabolism Up-Regulation - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Background Sclerotherapy with OK-432 is recommended as a first-line treatment for lymphatic malformations. However, 40% of patients show poor response, defined by involution to
ISSN:	0022-4804 1095-8673
DOI:	10.1016/j.jss.2013.09.037